BioPartnering Europe (BPE) Features Informative Sessions on the Hottest Themes in Biotech Today.LONDON London, city, Canada London, city (1991 pop. 303,165), SE Ont., Canada, on the Thames River. The site was chosen in 1792 by Governor Simcoe to be the capital of Upper Canada, but York was made capital instead. London was settled in 1826. -- Technology Vision Group LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control (TVG TVG TV Guide (magazine) TVG Televisión de Galicia TVG Tierversuchsgegner (German: Antivivisection) TVG Television Games Network TVG Toronto Venture Group TVG Tri Valley Growers TVG Time-Variable Gain ) is pleased to announce program details for the 14th Annual BioPartnering Europe Europe (y  r`əp), 6th largest continent, c.4,000,000 sq mi (10,360,000 sq km) including adjacent islands (1992 est. pop. 512,000,000). (BPE BPEabbr. Bachelor of Physical Education ) http://www.techvision.com/bpe conference which will be held in London, UK, on October October: see month. 8-10th 2006. One of the hallmarks of BPE, and reasons for its continued success, is its innovative and informative program which features some of the hottest themes in the biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. industry today. This year BPE will present five BioPartnering Leadership Sessions, four Sponsor Workshops and 130 company presentations that aim to highlight key issues and themes through topical topical /top·i·cal/ (top´i-k'l) pertaining to a particular area, as a topical antiinfective applied to a certain area of the skin and affecting only the area to which it is applied. top·i·cal adj. debate, as well as providing the perfect platform for biotech companies seeking potential partners and business opportunities. With well over 700 international delegates now registered to attend, BPE is proving to be as popular as ever, attracting key decision makers from the biotechnology, pharmaceutical and financial industries. One of the key features of BPE are the BioPartnering Leadership Sessions, where some of the most important issues effecting the growth of the life-science industry today are debated by a group of key decision makers. This year's opening session will focus on 'Equity Deals: A New Strategic Paradigm'. This session will look at how recent equity deals appear to indicate that big pharma is willing to make major investments in emerging biotech and drug development companies themselves, either has an acquisition strategy or prior to a liquidity event such as an IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. , in order to gain access to innovative biotech products. Other sessions in this series will look at: --The Future of Biotechnology Deal-Making --Mergers and Acquisitions: Trend or Fashion in Driving Corporate Development --Strategic Deals That Create Value --Creating Successful Partnerships: Lessons from the Frontline front·line also front line n. 1. A front or boundary, especially one between military, political, or ideological positions. 2. Basketball See frontcourt. 3. Football The linemen of a team. Another popular feature of BPE are the Open House presentations, where 100 emerging biopharmaceutical and diagnostic companies will host 2.5 hour interactive multimedia sessions designed to combine the detailed information of a podium podium In architecture, a pedestal on a large scale. It may be any of various elements that form the base of a structure, such as the platform forming the floor and substructure of a Classical temple, a low wall supporting columns, or the structurally or decoratively presentation with the feel of a business development meeting. "Compared to other events I have been to, BPE is just the right size to promote deal networking and deal-making," stated Ronald Hee, Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. Manager for Cygenics, Ltd., a stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs company based in Melbourne Melbourne, city, Australia Melbourne, city (1991 pop. 2,761,995), capital of Victoria, SE Australia, on Port Phillip Bay at the mouth of the Yarra River. Melbourne, Australia's second largest city, is a rail and air hub and financial and commercial center. , Australia Australia (ôstrāl`yə), smallest continent, between the Indian and Pacific oceans. With the island state of Tasmania to the south, the continent makes up the Commonwealth of Australia, a federal parliamentary state (2005 est. pop. and a returning Open House presenter at BPE. "Having companies exhibit for only a few hours is a brilliant way to showcase more companies in a limited time." biopartnering.com & video profiles foster B2B (Business to Business) Refers to one business communicating with or selling to another. See B2B e-commerce, B2C and B2G. B2B - business to business opportunities BPE delegates will once again be able to search partnering opportunities through keyword searches of detailed profiles on all companies, contact other delegates, arrange private meetings, and reserve meeting rooms in advance of the conference. In addition, biopartnering.com now offers a unique component - video profiles. This exciting new feature will give Open House and Emerging Company presenters the ability to add a short video to their biopartnering.com profile and thus promote their company in a dynamic and engaging manner. Full details about BioPartnering Europe online at: http://www.techvision.com. Conference Sponsors and Supporters Producer: Technology Vision Group LLC Premium Sponsors AstraZeneca, Taylor Wessing Gold Sponsors Cooley Godward LLP, Deloitte, Ferghana Partners Group, Wyeth Silver Sponsors Amgen, Bristol-Myers Squibb Company, Genentech, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, Roche, TAP Pharmaceutical Products Inc., Welsh Development Agency - Bioscience Unit Conference Sponsors BioQuebec, Farris, Vaughan, Wills, & Murphy LLP, Genzyme, Life Science Analytics, NovaQuest, Solomon-Page Group LLC Conference Supporters BayBio, BioCentury, Business Wire, Citigate, European Biopharmaceutical Review, Global Bioscience Partnership, Nature Biotechnology, Red Herring, U.S. Commercial Service Official Carrier British Airways Emerging Company Presenters Alchemia Limited, Amorfix Life Sciences Ltd., Antibe Therapeutics Inc., Athenagen, Avexa Limited, BioXell SpA, Borean Pharma A/S, BT Pharma, Celldex Therapeutics, Clera, Inc., EcoBiotics Ltd., GammaCan Int. Inc., Haptogen Ltd., hemoCORM, Karus Therapeutics, Lymphosign Inc., Mimetogen Pharmaceuticals, MNLpharma Ltd., ODC Therapy, PolyMedix Inc., ProtAffin Biotechnologie AG, Psynova Ltd., Rincon Pharmaceuticals, Inc., SantoSolve, Senexis Ltd., Synosis Therapeutics, Syntaxin, Y's Therapeutics, Zyentia Limited Open House Presenters ACE BioSciences A/S, Acrux Ltd., Aegera Therapeutics Inc., AerovectRx Corporation, AlgoNomics NV, Alligator Bioscience, amaxa GmbH, Ambit Biosciences, AmpliMed Corporation, Antisoma, Array BioPharma Inc., Arrow Therapeutics Ltd., Asperva Pharmaceuticals, Astex Therapeutics Ltd., Avecia Limited, Avera Pharmaceuticals, Inc., Avid Bioservices, Avidex Limited, Banner Pharmacaps, BioFocus, Biolex Therapeutics, Boston Life Sciences, Inc., Callisto Pharmaceuticals, Cell Genesys, Inc., CombinatoRx, Covx, Curis Pharmaceuticals, Cygenics, Ltd., Cylene Pharmaceuticals Inc., Cytokinetics, Inc., Dako North America, deltaDot, Digilab BioVisioN GmbH, Dimera Inc., DIREVO Biotech AG, Dyax Corp., Emergent Biosolutions, Evolutec, Evotec (UK) Ltd., ExonHit Therapeutics, Faust Pharmaceuticals, Favrille, Inc., Gala Biotech, a business unit of Cardinal Health, GangaGen Inc., Health Protection Agency, Icagen, Inc., ImmuPharma PLC, INC DataSpectrum, Indevus Pharmaceuticals, Inc., Ingenium Pharmaceuticals AG, InNexus Biotechnology Inc., Intendis GmbH, Intermune, Inc., Istituto Superiore di Sanita, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Jurilab Ltd., Liponex Inc., Locus Pharmaceuticals Inc., MaxCyte, Inc., Medicago Inc., MedPharm Ltd, Miltenyi Bioprocess, MolMed SpA, MorphoSys AG, Nektar Therapeutics, Nerites Corporation, Neuren Pharmaceuticals Inc., Novozymes A/S, OctoPlus, Orient EuroPharma Ltd., Oxford Genome Sciences, Oxxon Therapeutics Ltd., Paradigm Therapeutics Ltd., Perceptronix Medical Inc., Phylogica Ltd., PIramed Ltd., PLx Pharma, Portola Pharmaceuticals, PTC Therapeutics, Inc., RNTech, Sapphire Therapeutics, Scottish Biomedical, SGX Pharmaceuticals, Inc., SR Pharma / Atugen AG, Stem Cell Therapeutics, Threshold Pharmaceuticals, TiGenix NV, TopoTarget UK Ltd., Transgene S.A., Tranzyme Pharma, Trigen Holdings AG, Tripos Discovery Research Ltd., UCB Celltech, Warwick Effect Polymers Ltd., Welichem Biotech Inc., Xenome Ltd, XOMA Ltd., ZIOPHARM Oncology, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion